Stocktoria

HARVARD BIOSCIENCE INC HBIO

Nasdaq · stock · Laboratory Analytical Instruments · website · IPO 2013-10-21 · LEI

HARVARD BIOSCIENCE INC (HBIO) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $86.5M at a -65.5% net margin.

Chart by TradingView
24/100
Stocktoria Quality Score · grade D
4/9
Piotroski F — financial health
-10.45
Altman Z″ — distress risk · distress
Dividend yield · no dividend

Quality score trend · recomputed for each fiscal year

Piotroski F /9
7 4 4 5 6 3 6 2 0 4 2017201820192020202120222023202420252025
Altman Z″
1.47 -0.01 -0.29 -0.45 0.00 -1.21 -1.10 -3.86 -10.45 2017201820192020202120222023202420252025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$6.17 as of 2026-08-01 · +23.4% 1y
$4.40$7.6052-wk
Market cap USD$27M
Net margin 5y avg-22.5%
Return on equity 5y avg-107.7%
Beta1.51
Employees316

Analyst price target

$6.00 -2.8% vs last
· 1 analysts
target range $6.00 – $6.00

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Smart money · insiders, last 12 months

Insiders net bought +$177,304 on the open market · 4 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 9y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 45%
Net marginstronger than 25%
Return on equitystronger than 4%
Revenue growthstronger than 17%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 4/9 tests passed

Altman Z″ components · distress zone

ComponentValue
Working capital / assets0.328
Retained earnings / assets-2.681
EBIT / assets-0.607
Equity / liabilities0.207

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
HBIOHARVARD BIOSCIENCE INC4/9-10.45-8.1%
PRPOPrecipio, Inc.7/9-13.13+28%
QTRXQuanterix Corp1/9-1.83+1.1%
RPIDRAPID MICRO BIOSYSTEMS, INC.2/9+19.7%
EYPTEyePoint, Inc.1/9-3.58-27.5%
BNGOBionano Genomics, Inc.3/9-7.4%
SEERSeer, Inc.3/94.62+17%

All Manufacturing companies →

About HARVARD BIOSCIENCE INC

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

FAQ

Is HBIO financially healthy?

HARVARD BIOSCIENCE INC's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.

Does HBIO pay a dividend?

No, HARVARD BIOSCIENCE INC does not currently pay a dividend.

How profitable is HBIO?

In FY2025, HARVARD BIOSCIENCE INC had a net margin of -65.5% and a return on equity of -412.8%.

What is the analyst price target for HBIO?

The average Wall-Street price target for HARVARD BIOSCIENCE INC is $6.00, about 2.8% below the recent price, from 1 analysts.

Is HBIO a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on HARVARD BIOSCIENCE INC: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.